Shandong Jincheng Pharmaceutical Group Second Quarter 2024 Earnings: EPS: CN¥0.12 (vs CN¥0.13 in 2Q 2023)
Shandong Jincheng Pharmaceutical Group (SZSE:300233) Second Quarter 2024 Results
Key Financial Results
- Revenue: CN¥826.9m (down 5.6% from 2Q 2023).
- Net income: CN¥47.6m (down 7.6% from 2Q 2023).
- Profit margin: 5.8% (in line with 2Q 2023).
- EPS: CN¥0.12 (down from CN¥0.13 in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Shandong Jincheng Pharmaceutical Group shares are down 22% from a week ago.
Risk Analysis
It's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Shandong Jincheng Pharmaceutical Group, and understanding it should be part of your investment process.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SZSE:300233
Shandong Jincheng Pharmaceutical Group
Researches and develops, produces, markets, and sells Cephalosporin intermediates in China and internationally.
Solid track record with excellent balance sheet and pays a dividend.